CAJ | 학술논문

目的：探讨三氧化二砷（arsenic trioxide，As2O3）与传统药物地塞米松（Dexamethasone，DXM）、依托泊苷（Etoposide， VP-16）、甲氨蝶呤（Methotrexate，MTX）和新型药物硼替佐米（Bortezomib，BTZ）、组蛋白去乙酰化酶抑制剂-辛二酰苯胺异羟肟酸（suberoylanilide hydroxamic acid，SAHA）联合对人皮肤T细胞淋巴瘤（CTCL）细胞系Hut-78、Hut-102细胞的增殖抑制作用。方法：不同浓度的As2O3单药或与DXM/VP-16/MTX/BTZ/SAHA联合作用于Hut-78、Hut-102细胞48 h后，采用MTT法检测细胞增殖抑制率，应用联合指数分析两药是否具有协同效应。结果：As2O3、DXM、VP-16、MTX、BTZ、SAHA单药对Hut-78、Hut-102细胞的增殖均具有显著的抑制作用，呈剂量依赖性，培养48h的半数抑制浓度分别为5μmol/L、500μg/L、2.5μg/L、1μg/L、10μmol/L、2.5μmol/L。As2O3与DXM/VP-16/MTX/BTZ/SAHA联合时具有协同效应，抗肿瘤作用更为显著。结论：As2O3单药及其与DXM/VP-16/MTX/BTZ/SAHA联合在体外可有效抑制CTCL细胞增殖。As2O3是一种很有前景的治疗CTCL的药物，As2O3与DXM/VP-16/MTX/BTZ/SAHA等传统或新型药物联合可为CTCL临床的治疗提供实验依据。
목적：탐토삼양화이신（arsenic trioxide，As2O3）여전통약물지새미송（Dexamethasone，DXM）、의탁박감（Etoposide， VP-16）、갑안접령（Methotrexate，MTX）화신형약물붕체좌미（Bortezomib，BTZ）、조단백거을선화매억제제-신이선분알이간우산（suberoylanilide hydroxamic acid，SAHA）연합대인피부T세포림파류（CTCL）세포계Hut-78、Hut-102세포적증식억제작용。방법：불동농도적As2O3단약혹여DXM/VP-16/MTX/BTZ/SAHA연합작용우Hut-78、Hut-102세포48 h후，채용MTT법검측세포증식억제솔，응용연합지수분석량약시부구유협동효응。결과：As2O3、DXM、VP-16、MTX、BTZ、SAHA단약대Hut-78、Hut-102세포적증식균구유현저적억제작용，정제량의뢰성，배양48h적반수억제농도분별위5μmol/L、500μg/L、2.5μg/L、1μg/L、10μmol/L、2.5μmol/L。As2O3여DXM/VP-16/MTX/BTZ/SAHA연합시구유협동효응，항종류작용경위현저。결론：As2O3단약급기여DXM/VP-16/MTX/BTZ/SAHA연합재체외가유효억제CTCL세포증식。As2O3시일충흔유전경적치료CTCL적약물，As2O3여DXM/VP-16/MTX/BTZ/SAHA등전통혹신형약물연합가위CTCL림상적치료제공실험의거。
Objective:To investigate the in vitro effect of arsenic trioxide (As2O3) alone and in combination with dexamethasone (DXM), etoposide (VP-16), methotrexate (MTX), bortezomib (BTZ), and suberoylanilide hydroxamic acid (SAHA) on the growth of human cutaneous T cell lymphoma (CTCL) cells Hut-78 and Hut-102. Methods:Hut-78 and Hut-102 cells were cultured with different concentrations of As2O3, DXM, VP-16, MTX, BTZ, and SAHA alone and As2O3 in combination with DXM, VP-16, MTX, BTZ, or SAHA for 48 h. The effects of the different samples on Hut-78 and Hut-102 cell proliferation were determined by MTT assay. Analyses using CalcuSyn software were performed to determine whether the combination of As2O3 with DXM, VP-16, MTX, BTZ, or SAHA in-duced synergistic cytoxicity. Results:As2O3, DXM, VP-16, MTX, BTZ, and SAHA alone significantly inhibited the growth of Hut-78 and Hut-102 cells in a dose-dependent manner, with a 50%inhibiting concentration of 5μmol/L, 500μg/mL, 2.5μg/mL, 1μg/mL, 10μmol/L, and 2.5μmol/L individually after 48 h of culture. As2O3 with DXM, VP-16, MTX, BTZ, or SAHA showed remarkable antitu-mor efficacy compared with that of individual applications. Conclusion:As2O3 alone or combined with DXM, VP-16, MTX, BTZ, or SAHA significantly inhibited Hut-78 and Hut-102 cell growth in vitro. This study demonstrated that As2O3 with DXM, VP-16, MTX, BTZ, or SAHA presents synergistic antitumor effects on CTCL cells and may be an optimal regimen in clinical trials of CTCL.